Science & Health
A growing body of neuroscience research is beginning to map how cannabis interacts with the brain's response to other substances — and a new study adds an important chapter to that story. According to research reported by PsyPost, cannabis use appears to alter how the human brain processes nicotine, a finding with potential implications for the significant proportion of cannabis consumers who also use tobacco or nicotine products.
What the Research Found
The study used neuroimaging techniques to examine brain activity in individuals who use cannabis, comparing their responses to nicotine cues against those of non-cannabis users. Researchers observed measurable differences in how the brain's reward and processing circuits responded, suggesting that cannabis use may modulate — rather than simply coexist alongside — nicotine sensitivity at a neurological level.
While the precise mechanisms are still being investigated, the working hypothesis centres on the endocannabinoid system, the network of receptors that THC (tetrahydrocannabinol) interacts with. This system overlaps substantially with pathways that regulate dopamine release — the same pathways central to nicotine's effects on the brain. Repeated cannabis use may sensitise or desensitise aspects of this shared circuitry in ways that change how nicotine is experienced and processed.
Caveats Worth Noting
Before drawing firm conclusions, the study's limitations deserve careful attention. Neuroimaging research of this kind typically involves relatively small, controlled samples — making it difficult to generalise findings across the full diversity of cannabis consumption patterns, frequencies, and product types. The study did not, according to the PsyPost report, distinguish between different modes of cannabis consumption (smoked, vaporised, or ingested), which may have distinct pharmacokinetic profiles relevant to brain exposure.
Confounding variables are also a real concern in this field. People who use both cannabis and tobacco often differ from single-substance users across a range of factors — including age of first use, socioeconomic background, mental health history, and frequency of consumption — any of which could independently shape brain activity patterns. The research appears to represent an early-stage finding rather than a replicated, settled conclusion, and independent replication across larger and more diverse populations will be needed before clinicians or policymakers should treat it as established science.
Why It Matters for Dual-Use Consumers
The practical relevance of this research lies in who it describes. In Malta and across much of Southern Europe, cannabis is commonly consumed mixed with tobacco — a habit deeply embedded in the cultural history of cannabis use on the continent, and one that complicates both the health picture and harm reduction messaging considerably.
ARUC (Authority on the Responsible Use of Cannabis), Malta's regulatory body overseeing the adult-use cannabis framework established under Malta's 2021 cannabis reform (Chapter 628 of the Laws of Malta), has consistently supported harm reduction messaging that addresses polysubstance use. Cannabis Harm Reduction Associations (CHRAs) — the licensed, non-profit clubs through which adult Maltese consumers can legally access cannabis — are well positioned to relay this kind of emerging research to their members. Several CHRAs have previously distributed harm reduction materials specifically addressing the risks of tobacco co-use, including the role tobacco mixing plays in increasing the overall health burden of cannabis consumption.
The neurological dimension highlighted by this research adds nuance to that conversation. If cannabis genuinely alters nicotine processing, it raises questions not only about the health implications of combined use, but also about what this means when cannabis consumers attempt to reduce or stop nicotine use — and whether standard nicotine cessation approaches may need adjustment for this population.
A Broader European Picture
The European Union Drugs Agency (EUDA), the Lisbon-based body responsible for monitoring drug trends and related health issues across EU member states, has noted in recent reporting cycles that poly-drug use — the concurrent use of cannabis alongside tobacco, alcohol, or other substances — remains among the more common patterns observed across Europe. Understanding how substances interact at a neurological level is increasingly seen as essential to crafting effective harm reduction strategies that reflect how people actually consume, rather than how regulators might prefer they did.
This research does not suggest that cannabis causes nicotine addiction, nor does it support the older and largely discredited "gateway" framing of cannabis as a stepping stone to harder substance use. What it does suggest is that the brain is not a passive recipient of multiple substances operating independently — and that the interaction between cannabis and nicotine at the neurological level is more dynamic than previously understood.
As cannabis regulation matures across Europe and adult consumers have increasingly legal and transparent access to information about what they are consuming, research of this kind underscores the value of continued investment in neuroscience that reflects real-world consumption patterns. For harm reduction practitioners and healthcare professionals advising cannabis consumers, the takeaway is practical: the question of tobacco co-use is not peripheral to cannabis health discussions — it belongs at the centre of them.
Sources:
PsyPost — Cannabis use alters how the human brain processes nicotine, new research suggests
Featured image: Photo by Google DeepMind on Pexels
Members Discussion